COVID-19 Policy Statement

Pharmaceutical Counterfeits Threaten $1 Billion Pipeline of Product

Pharmaceutical Counterfeits Threaten $1 Billion Pipeline of Product

The Issue

Counterfeit copies of a major pharmaceutical brand were discovered in the US market. With no security measures in place to allow patients or inspectors to readily distinguish authentic from counterfeit goods, both patient welfare and the manufacturer’s reputation were under threat. Given such risks, the $1 billion of authentic product, which was in the distribution pipeline, could not be sold without some means of allowing patients and retailers to verify that the product was authentic.

The Solution

The product was repackaged to include a variety of authentication features that could be identified by patients and inspectors, both in the field and in the laboratory. These included:

  • Overt color-shifting ink that could be readily distinguished by patients
  • Covert, machine-readable inks that that can be detected by inspection staff with appropriate readers in the field
  • Forensic markers that can only be detected under laboratory analysis

The printed solutions were applied to packaging, labels and other components using a variety of printing methods. Moreover, the solution was developed by Authentix and approved by the customer and the FDA within four weeks.

The Outcome

The strategic solution provided a secure means of distinguishing authentic from counterfeit goods, thereby restoring confidence in the brand among physicians, pharmacists and patients. The manufacturer was able to mitigate the risk of potential lawsuits. Furthermore, the $1 billion of product frozen within the supply chain was released for sale and the expense of a full product recall was averted.

COVID-19 Policy Statement


At Authentix, our mission to safeguard the integrity of global commerce is our priority as we continue to focus on customer needs with the challenges presented by the COVID-19 health emergency. Our corporate leadership team is monitoring the situation closely and its potential impact on supply chain continuity.

Our first and foremost commitment is to the health and safety of all Authentix employees. As we have said when faced with other similar infectious disease situations, we will never force Authentix employees to travel to geographic areas where they are uncomfortable or that present an increased risk of exposure to infectious disease.

Effective through April 30, 2020, we have closed the Addison Texas Facility to all personnel who do not require facility equipment to conduct their job, allowing for only those functions such as production/shipping/testing as needed to continue to serve our customers. We have banned all visitors to the Addison Texas Facility as well. We encourage all Authentix sites to enact a similar ban for employee safety and to restrict visitors, but realize this restriction is subject to local needs. We have further banned all air/train travel for all employees for Authentix business purposes. We ask that all customers, vendors or suppliers support these efforts and for those who present themselves at Authentix locations to respect and adhere to our policies and procedures that may limit access on this temporary basis.

We will continue to communicate regularly with our suppliers and updating contingency plans to ensure against any adverse impact or disruption to our customers, acknowledging that we are however subject to continued government restrictions and limited availability of transportation that may continue during this time. We encourage you to reach out to your Authentix point of contact with any questions or concerns.


Back To Top